3.23 USD
-0.76 (-19.05%)
2.85 USD
-0.38 (-11.76%)
Overall TBIO gets a fundamental rating of 1 out of 10. We evaluated TBIO against 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of TBIO have multiple concerns. TBIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- TBIO had negative earnings in the past year.
- In the past year TBIO has reported a negative cash flow from operations.
- In the past 5 years TBIO always reported negative net income.
- In the past 5 years TBIO always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of TBIO (-98.37%) is worse than 92.98% of its industry peers.
- The Return On Equity of TBIO (-521.49%) is worse than 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -98.37% | ||
| ROE | -521.49% | ||
| ROIC | N/A |
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of TBIO (47.88%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of TBIO has grown nicely.
- TBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, TBIO has more shares outstanding
- The debt/assets ratio for TBIO has been reduced compared to a year ago.
2.2 Solvency
- TBIO has an Altman-Z score of -6.48. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
- TBIO has a Altman-Z score of -6.48. This is amonst the worse of the industry: TBIO underperforms 91.23% of its industry peers.
- TBIO has a Debt/Equity ratio of 0.54. This is a neutral value indicating TBIO is somewhat dependend on debt financing.
- TBIO has a worse Debt to Equity ratio (0.54) than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.48 |
ROIC/WACCN/A
WACC14.42%
2.3 Liquidity
- TBIO has a Current Ratio of 1.89. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
- TBIO's Current ratio of 1.89 is on the low side compared to the rest of the industry. TBIO is outperformed by 61.40% of its industry peers.
- TBIO has a Quick Ratio of 1.72. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of TBIO (1.72) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
- The earnings per share for TBIO have decreased strongly by -1673.33% in the last year.
- Looking at the last year, TBIO shows a very negative growth in Revenue. The Revenue has decreased by -43.65% in the last year.
- The Revenue has been growing by 61.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
3.2 Future
- TBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.72% yearly.
- Based on estimates for the next years, TBIO will show a very negative growth in Revenue. The Revenue will decrease by -40.92% on average per year.
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for TBIO. In the last year negative earnings were reported.
- Also next year TBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as TBIO's earnings are expected to decrease with -29.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for TBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELESIS BIO INC / TBIO FAQ
Can you provide the ChartMill fundamental rating for TELESIS BIO INC?
ChartMill assigns a fundamental rating of 1 / 10 to TBIO.
What is the valuation status of TELESIS BIO INC (TBIO) stock?
ChartMill assigns a valuation rating of 0 / 10 to TELESIS BIO INC (TBIO). This can be considered as Overvalued.
Can you provide the profitability details for TELESIS BIO INC?
TELESIS BIO INC (TBIO) has a profitability rating of 1 / 10.
What is the financial health of TELESIS BIO INC (TBIO) stock?
The financial health rating of TELESIS BIO INC (TBIO) is 2 / 10.
What is the expected EPS growth for TELESIS BIO INC (TBIO) stock?
The Earnings per Share (EPS) of TELESIS BIO INC (TBIO) is expected to decline by -122.26% in the next year.